NCT03270059View on ClinicalTrials.gov

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2027

Conditions
Central Nervous System NeoplasmCranial Nerve DisorderMetastatic Malignant Neoplasm in the Brain
Interventions
DRUG

Ferumoxytol

Given IV

DRUG

Gadolinium

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT03270059 - Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System | Biotech Hunter | Biotech Hunter